Building on their previous research focusing on vaccination within a tumor (intratumoral) for the most common form of pancreatic cancer, investigators from Rutgers Cancer Institute of New Jersey and Rutgers Robert Wood Johnson Medical School have shown that in a mouse model of early stage resected pancreatic cancer, intratumoral vaccination induces an anti-tumor response that results in a significant improvement in overall survival.
Results of the work were presented as part of a poster presentation at the 70th Annual Society of Surgical Oncology Cancer Symposium held this past week in Seattle.
The group’s previous work focused on the investigational vaccine known as PANVAC. PANVAC contains gene additives that might stimulate a person’s immune system to recognize and develop an immune response to the disease. Read more . . .